Immuron LimitedASX: IMC

US DoD Naval Medical Research Center Clinical Update

· Issued by Immuron Limited

Filed with ASX · · 2 pages · English

Key Points • Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed. • IND submission to the U.S. Food and Drug administration (FDA) planned for Q1 CY2022 to support Two human phase II clinical trials. • One trial will focus on the ability of the hyperimmune product to prevent infectious diarrhea caused by ETEC and schedul

Immuron Limited on 6ix

Earlier from Immuron

Later from Immuron

All Immuron news releases